TD Cowen on Compass Pathways (CMPS): 'We think DEA reclassification to schedule 3 after approval is likely'

July 7, 2026 3:53 PM

TD Cowen analyst Ritu Baral reiterated a Buy rating and $29.00 price target on Compass Pathways (NASDAQ: CMPS).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider

Log in to your account:

TD Cowen on Compass Pathways (CMPS): 'We think DEA reclassification to schedule 3 after approval is likely'

Categories